CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial is a research paper published in Investigational New Drugs (2024). On theSindex it has a DataRank of 1.3. It has been cited 67 times, with 67 citing works in its 1-hop citation network.
Scored on demand from live citation data
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.633
From this paper's citation signal
Citation Network Contribution
0.716
From 52 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 67 citers.
National Institutes of Health
Grant: 1R01CA233585-01
Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancer
Canadian Institutes of Health Research
Grant: unidentified
unidentified
NCI NIH HHS
Grant: R01 CA233585
NCI NIH HHS
Grant: 1R01CA233585-04
Fields of Study
MeSH Terms
Keywords